These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31433678)

  • 1. Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases.
    Lanza JS; Pomel S; Loiseau PM; Frézard F
    Expert Opin Drug Deliv; 2019 Oct; 16(10):1063-1079. PubMed ID: 31433678
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
    Carneiro G; Aguiar MG; Fernandes AP; Ferreira LA
    Expert Opin Drug Deliv; 2012 Sep; 9(9):1083-97. PubMed ID: 22724539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
    Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.
    Frézard F; Aguiar MMG; Ferreira LAM; Ramos GS; Santos TT; Borges GSM; Vallejos VMR; De Morais HLO
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal Amphotericin B Treatment and the Leishmaniases.
    Berman J
    Am J Trop Med Hyg; 2019 Oct; 101(4):727-728. PubMed ID: 31482790
    [No Abstract]   [Full Text] [Related]  

  • 6. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation.
    Gupta PK; Jaiswal AK; Kumar V; Verma A; Dwivedi P; Dube A; Mishra PR
    Mol Pharm; 2014 Mar; 11(3):951-63. PubMed ID: 24495144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis.
    Mohamed-Ahmed AH; Brocchini S; Croft SL
    Curr Opin Infect Dis; 2012 Dec; 25(6):695-702. PubMed ID: 23147810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing efficacy of amphotericin B through nanomodification.
    Vyas SP; Gupta S
    Int J Nanomedicine; 2006; 1(4):417-32. PubMed ID: 17722276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
    de Carvalho RF; Ribeiro IF; Miranda-Vilela AL; de Souza Filho J; Martins OP; Cintra e Silva Dde O; Tedesco AC; Lacava ZG; Báo SN; Sampaio RN
    Exp Parasitol; 2013 Oct; 135(2):217-22. PubMed ID: 23891944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
    Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
    Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.
    Daftarian PM; Stone GW; Kovalski L; Kumar M; Vosoughi A; Urbieta M; Blackwelder P; Dikici E; Serafini P; Duffort S; Boodoo R; Rodríguez-Cortés A; Lemmon V; Deo S; Alberola J; Perez VL; Daunert S; Ager AL
    J Infect Dis; 2013 Dec; 208(11):1914-22. PubMed ID: 23901083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis.
    Italia JL; Kumar MN; Carter KC
    J Biomed Nanotechnol; 2012 Aug; 8(4):695-702. PubMed ID: 22852479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems.
    Wagner V; Minguez-Menendez A; Pena J; Fernández-Prada C
    Curr Pharm Des; 2019; 25(14):1582-1592. PubMed ID: 31223081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.
    Gupta PK; Jaiswal AK; Asthana S; Verma A; Kumar V; Shukla P; Dwivedi P; Dube A; Mishra PR
    Pharm Res; 2015 May; 32(5):1727-40. PubMed ID: 25425053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.
    Serrano DR; Hernández L; Fleire L; González-Alvarez I; Montoya A; Ballesteros MP; Dea-Ayuela MA; Miró G; Bolás-Fernández F; Torrado JJ
    Int J Pharm; 2013 Apr; 447(1-2):38-46. PubMed ID: 23438978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment.
    Chávez-Fumagalli MA; Ribeiro TG; Castilho RO; Fernandes SO; Cardoso VN; Coelho CS; Mendonça DV; Soto M; Tavares CA; Faraco AA; Coelho EA
    Rev Soc Bras Med Trop; 2015; 48(3):235-42. PubMed ID: 26107999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.